Zogenix to Participate in the Stifel 2020 Virtual Healthcare Conference

Rhea-AI Summary

Zogenix, a biopharmaceutical company focused on rare disease therapies, announced that Stephen J. Farr, Ph.D., and Michael P. Smith will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 10:00 AM Eastern Time. The event will be streamed live and archived for 90 days on Zogenix's Investor Relations website. Zogenix is known for its FDA-approved therapy, FINTEPLA®, for Dravet syndrome and is developing additional treatments for other rare conditions.

EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, and Treasurer, will participate in a fireside chat on Wednesday, November 18, 2020, at the Stifel 2020 Virtual Healthcare Conference.

Zogenix Fireside Chat Details
Date:	Wednesday, November 18, 2020
Time:	10:00 AM Eastern Time

The fireside chat will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About Zogenix

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.  

CONTACTS:

Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732
corpcomms@zogenix.com

Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578
britchie@lifesciadvisors.com

Media
Stefanie Tuck
Vice President, Porter Novelli
+1 (978) 390-1394
stefanie.tuck@porternovelli.com 

FAQ

When is Zogenix's fireside chat at the Stifel 2020 Virtual Healthcare Conference?

The fireside chat will take place on November 18, 2020, at 10:00 AM Eastern Time.

Who will represent Zogenix at the fireside chat?

Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President and CFO, will participate.

Where can I watch the Zogenix fireside chat?

The fireside chat will be webcast live and can be accessed on Zogenix's Investor Relations website.

What is Zogenix known for?

Zogenix is recognized for developing therapies for rare diseases, including the FDA-approved FINTEPLA® for Dravet syndrome.

What other therapies is Zogenix developing?

Zogenix is working on additional therapies, including treatments for Lennox-Gastaut syndrome and TK2 deficiency.